Chicago Escorts: Coming to Your iPad in 2013: DSM-5 and Changes in Biopharma Research Methods

Added to the “symptom versus causes” debate on psychiatric diagnoses are concerns related to the influence of the biopharmaceutical industry on the practice of psychiatry where “patients who seek psychiatric help . . . stand a good chance of being diagnosed with a disease that doesn’t exist” (1, 2, 5, 9, 12, 13). This has led to accusations of collusion between the industry and key opinion leaders (KoLs) in the psychiatric field, who are perceived to be turning the specialty into a non-PC “pharmaceutical brothel“(14). This perception certainly has not been helped by recent Senate conflict-of-interest cases involving seven KoLs in psychiatry or by recent comments from the head of the National Institute of Mental Health (NIMH), who noted that “the close connection between leading psychiatrists and the pharmaceutical industry, once a sign of progress . . . is now cited as evidence of a corrupt influence” (13, 15, 16).

See the full article from “BioWorld Online”